Effective January 1, 2026, Medi-Cal Rx is excluding coverage for GLP-1 medications prescribed for weight loss: [12] Wegovy, Zepbound, Saxenda: Completely removed from the Contract Drugs List for weight loss Ozempic, Mounjaro, Rybelsus: Restricted to Type 2 diabetes onlyweight loss claims will auto-deny Existing prior authorizations end December 31, 2025 Exceptions: Members under age 21 may still qualify via EPSDT Non-weight-loss indications (Zepbound for OSA, Wegovy for cardiovascular) may still get PA approval This does NOT affect Kaiser commercial or employer-sponsored plansonly Medi-Cal members
Is infusion therapy painful
218 In addition, it also plays an important role in maintaining transmitter homeostasis, in which glutamate and GABA play particularly important roles
One survey shows about 12% of U.S
Improve insulin sensitivity Stable blood sugar reduces energy slumps, mood swings, and the long-term risk of type 2 diabetes
#3 Slower gastric emptying Food remains in the stomach longer, increasing feelings of fullness